E
Eligo Bioscience
Biotech & Life Sciences · Paris, France · Founded 2014
Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing MoreLess
Eligo Bioscience is a cutting-edge biotechnology startup that focuses on developing targeted antimicrobial solutions using advanced synthetic biology. The company operates in the healthcare and biotechnology markets, addressing significant unmet medical needs related to the human microbiome—the community of trillions of bacteria living in and on our bodies. These bacteria are increasingly linked to a variety of severe diseases, including cancer, obesity, neurodegenerative diseases, and autoimmune disorders.
Eligo Bioscience's core innovation lies in its proprietary technology called "Eligobiotics." These are genetic circuits engineered to be delivered by bacteriophages—viruses that infect bacteria. These circuits can diagnose, eradicate, or modify specific bacterial populations within the microbiome. This targeted approach allows for precision treatment, minimizing the collateral damage to beneficial bacteria that is often seen with traditional antibiotics.
The company serves a diverse range of clients, including those in human and animal health, cosmetics, industrial biotechnology, and food industries. By addressing both medical and non-medical applications, Eligo Bioscience taps into multiple revenue streams. Their business model revolves around research and development, followed by commercialization of their Eligobiotics technology. They generate income through partnerships, licensing agreements, and direct sales of their products.
Eligo Bioscience has assembled a strong team of scientists, genome architects, and executives to translate their research into real-world applications. This multidisciplinary team is crucial for navigating the complex landscape of synthetic biology and genome engineering.
In summary, Eligo Bioscience is a pioneering company in the field of synthetic biology, focusing on precision microbiome engineering to tackle a wide range of health issues. Their innovative approach and diverse market applications position them as a significant player in the biotech industry.
Keywords: Biotechnology, Synthetic Biology, Microbiome, Antimicrobials, Healthcare, Precision Medicine, Genetic Engineering, Bacteriophages, R&D, Innovation.
Company overview
Eligo Bioscience company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Paris, France
- Employees
- 46
- Open positions
- 3
- Dealroom signal
- 76.0
Valuation & funding
Eligo Bioscience funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | May 2025 | $5M | — | French Government | ↗ |
| SERIES BOther financing | Dec 2023 | $30M | $122M | Sanofi Ventures · Bpifrance · Seventure Partners · Khosla Ventures | ↗ |
| SUPPORT PROGRAMOther financing | Jan 2021 | $0 | — | EIT Health | — |
| GRANTOther financing | Jun 2020 | $7M | — | CARB-X | — |
| GRANTOther financing | May 2019 | $3.1M | — | European Commission | — |
| GRANTOther financing | Jan 2019 | Undisclosed | — | ||
| EARLY VCOther financing | Apr 2018 | Undisclosed | — | ||
| EARLY VCOther financing | Jul 2017 | Khosla Ventures | — | ||
| SEEDOther financing | Jul 2015 | Seventure Partners | — | ||
| SUPPORT PROGRAMOther financing | Jan 2015 | Agoranov | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1.8M | 0% | −$6.6M | -362.4% |
| 2025 | $1.8M | 0% | −$6.6M | -362.4% |
| 2024 | $1.8M | 0% | −$6.6M | -362.4% |
| 2023 | $1.8M | 0% | −$6.6M | -362.4% |
| 2022 | $1.8M | +2.5% | −$6.6M | -362.4% |
| 2021 | $1.8M | -16.3% | −$6.6M | -371.4% |
| 2020 | $2.1M | — | −$2.8M | -131.9% |
Growth signals
Eligo Bioscience website traffic
Latest recorded traffic for Eligo Bioscience is 3.9K monthly website visits, up 143.8% over the last three months. Eligo Bioscience's team grew 7% over the past year.
Hiring
Open positions at Eligo Bioscience
Current openings linked to this company in Dealroom.
Comparisons
Eligo Bioscience compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Eligo Bioscience's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Eligo Bioscience has talent and traffic
team presence
In the news
Latest news about Eligo Bioscience
Recent press, funding announcements, and product moves mentioning Eligo Bioscience — open to read from the original sources.
Market sentiment
What the market is saying about Eligo Bioscience
An AI-synthesized read of the highest-engagement posts about Eligo Bioscience on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eligo Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.